Dechra Pharmaceuticals Plc

24 Cheshire Avenue, Cheshire Business Park,
Northwich, CW9 7UA
United Kingdom,
+44 1606 814 730
www.dechra.com

Dechra is an international specialist veterinary pharmaceuticals and relates products business. Its expertise is in the development, manufacturing and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.

M&A Summary

Buy vs Sell

Year ≤ '12 '13 '14 '15 '16 '17 T
Buy (1.0/yr) # 7 - 1 1 3 - 12
vol $334M $10M $246M $589M
Sell (0.4/yr) # - 2 - - - - 2
vol $135M $135M
  14

Top M&A Advisors

Financial Deals
Sign-up to View
1
Sign-up to View
1
Legal Deals
Sign-up to View
1

Deal Values

Buy # TOTAL
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest Putney, Inc.
$200M (2016-03-15)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View
Largest Dechra Pharmaceuticals - Services Segment
$135M (2013-07-10)

According to our data here at Mergr, Dechra Pharmaceuticals has acquired 12 companies, including 5 in the last 5 years. A total of 2 acquisitions came from private equity firms. It has also divested 2 assets.

Dechra Pharmaceuticals’ largest acquisition to date was in 2016, when it acquired Putney for $200M. It’s largest disclosed sale occurred in 2013, when it sold Dechra Pharmaceuticals - Services Segment to Patterson Companies for $135M. Dechra Pharmaceuticals has acquired in 3 different US states, and 8 countries. The Company’s most targeted sectors include life science (92%) and consumer services (9%).

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 419 life science companies that have made at least 1 acquisition, 25 have acquired at least 5 companies, and 4 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 24 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 4 platform acquisitions.

Join Mergr and gain access to Dechra Pharmaceuticals’ M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.


What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.1K Private Equity Firms
  • 110K M&A Transactions
  • 120K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.7K M&A Advisors
    (Investment Banks and Law Firms)
  • 38K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.